Saxagliptin

Saxagliptin is an oral anti-diabetic medication used to treat type 2 diabetes. It belongs to a class of drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors. Saxagliptin works by blocking the action of the DPP-4 enzyme, which breaks down incretin hormones. These hormones help the body increase insulin production after meals and decrease the amount of glucose produced by the liver. By inhibiting DPP-4, saxagliptin increases the levels of incretin hormones, thereby improving blood sugar control. FDA approved on July 31, 2009. It is grouped under the following drug class(es): DPP-4 inhibitors and Hypoglycemics. Its therapeutic use is listed as antidiabetic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Saxagliptin anhydrous and Saxagliptine. Its PubChem CID is 11243969.